Different patterns of cerebral perfusion in SLE patients with and without neuropsychiatric manifestations

Zhizheng Zhuo1,2 | Li Su3,4 | Yunyun Duan1 | Jing Huang1 | Xiaolu Qiu1 | Sven Haller5 | Haiyun Li2 | Xiaofeng Zeng3,4 | Yaou Liu1

1Department of Radiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
2School of Biomedical Engineering, Capital Medical University, Beijing, China
3Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, Beijing, China
4Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, National Clinical Research Center on Rheumatology, Ministry of Science & Technology, Beijing, China
5Department of Imaging and Medical Informatics, University Hospitals of Geneva and Faculty of Medicine of the University of Geneva, Geneva, Switzerland

Correspondence
Yaou Liu, MD, PhD, No. 119, the West Southern 4th Ring Road, Fengtai District, Beijing 100070, China. Email: yaouliu80@163.com
Xiaofeng Zeng, MD, PhD, No. 1 Shuaifuyuan, Dongcheng District, Beijing 100730, China. Email: xiaofeng.zeng@cstar.org.cn
Haiyun Li, PhD, Youanmen Street No. 10, Fengtai District, Beijing, 100069, China. Email: haiyunli@ccmu.edu.cn

Funding information
Beijing Natural Science fund, Grant/Award Number: 7133244; Beijing Nova Program, Grant/Award Number: xx2013045; National Science Foundation of China, Grant/Award Numbers: 81571597, 81571631, 81870958; The Chinese National Key Research R&D Program, Grant/Award Numbers: 2017YFC0907601, 2017YFC0907602, 2017YFC090760

Abstract
To investigate brain perfusion patterns in systemic lupus erythematosus (SLE) patients with and without neuropsychiatric systemic lupus erythematosus (NPSLE and non-NPSLE, respectively) and to identify biomarkers for the diagnosis of NPSLE using noninvasive three-dimensional (3D) arterial spin labeling (ASL). Thirty-one NPSLE and 24 non-NPSLE patients and 32 age- and sex-matched normal controls (NCs) were recruited. Three-dimensional ASL-MRI was applied to quantify cerebral perfusion. Whole brain, gray (GM) and white matter (WM), and voxel-based analysis (VBA) were performed to explore perfusion characteristics. Correlation analysis was performed to find the relationship between the perfusion measures, lesion volumes, and clinical variables. Receiver operating characteristic (ROC) analysis and support vector machine (SVM) classification were applied to differentiate NPSLE patients from non-NPSLE patients and healthy controls. Compared to NCs, NPSLE patients showed increased cerebral blood flow (CBF) within WM but decreased CBF within GM, while non-NPSLE patients showed increased CBF within both GM and WM. Compared to non-NPSLE patients, NPSLE patients showed significantly reduced CBF in the frontal gyrus, cerebellum, and corpus callosum. CBF within several brain regions such as cingulate and corpus callosum showed significant correlations with the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and the Systemic Lupus International Collaborating Clinics (SLICC) damage index scores. ROC analysis showed moderate performance in distinguishing NPSLE from non-NPSLE patients with AUCs > 0.7, while SVM analysis demonstrated that CBF within the corpus callosum achieved an accuracy of 83.6% in distinguishing NPSLE from non-NPSLE patients. Different brain perfusion patterns were observed between NPSLE and non-NPSLE patients. CBF measured by noninvasive 3D ASL could be a useful biomarker for the diagnosis and disease monitoring of NPSLE and non-NPSLE patients.

KEYWORDS
3D arterial spin labeling, neuropsychiatric systemic lupus erythematosus, perfusion, systemic lupus erythematosus

Zhizheng Zhuo and Li Su contributed equally to this study.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2019 The Authors. Human Brain Mapping published by Wiley Periodicals, Inc.
Neuropsychiatric systemic lupus erythematosus (NPSLE) is a severe and life-threatening type of SLE. It has a wide range of clinical neurological and psychiatric manifestations (e.g., stroke, epilepsy, cognitive deficits, psychosis, and mood disorders) that decrease quality of life (Ercan et al., 2015; Rhiannon, 2008). Complex underlying pathological mechanisms are reported in SLE, particularly in NPSLE, including neuroinflammation, demyelination, neuron injury, and vasculopathy (Sibblitt et al., 2010). It is crucial to differentiate NPSLE from SLE without neurologic or psychiatric symptoms (named non-NPSLE; Sarbu et al., 2015). However, the discrimination of NPSLE from non-NPSLE is difficult in a clinical setting, requiring stable and reliable biological and radiographical markers (Castellino, Govoni, Giacuzzo, & Trotta, 2008; Cervera et al., 2006; Sarbu, Bargalló, & Cervera, 2015).

Perfusion imaging has been used to assess the microvasculature changes in SLE patients. The cerebral hyperperfusion of frontal, temporal, and partial areas has been observed in NPSLE patients by positron emission tomography (PET) and single-photon emission computed tomography (SPECT) studies, which could provide early biomarkers for SLE (Kodama et al., 1995; Sahebkar, Rezaieyazdi, Khodashahi, Abbasi, & Ayatollahi, 2018). Recently, MR perfusion imaging studies with dynamic susceptibility contrast (DSC) reported that the cerebral blood volume (CBV) and cerebral blood flow (CBF) of certain specific brain regions (e.g., posterior cingulate gyrus) were highly related to NPSLE (Gasparovic et al., 2010; Papadaki et al., 2018; Wang et al., 2012; Zimny et al., 2014). Compared to normal controls (NC), both hyperperfusion and hypoperfusion, were illustrated within gray (GM) and white matter (WM) in SLE patients (Gasparovic et al., 2010; Papadaki et al., 2018; Wang et al., 2012; Zimny et al., 2014). Previous studies have demonstrated hypoperfusion within GM and WM in NPSLE compared to non-NPSLE (Papadaki et al., 2018; Wang et al., 2012). Accumulated evidence indicates that abnormal perfusion (CBF or CBV) is not specific to NPSLE because perfusion is also altered in non-NPSLE patients. Discordant results were shown in a few studies (Emmer et al., 2010; Waterlo et al., 2001). Emmer et al. (2010) used ROIs (regions of interest), including subcortical GM and central WM, to investigate the perfusion alterations in NPSLE but did not find any significant difference among groups (NPSLE patients, non-NPSLE patients, and NCs).

In clinical practice, the attribution of neuropsychiatric manifestations to SLE mainly depends on expert physician judgment. Neither clinical measurements nor conventional imaging has adequate diagnostic precision. The abovementioned PET and DSC-MRI perfusion imaging techniques have high sensitivity (80–100%) but low specificity (<67%) in diagnosing NPSLE (Castellino et al., 2008; Kao et al., 1999; Kao et al., 1999). PET, SPECT, or DSC-MRI are not suitable for every SLE patient due to irradiation or contrast injection.

Arterial spin labeling (ASL) imaging, which is a contrast agent-free perfusion imaging technique, has been validated as being useful for the evaluation of brain perfusion related to various neurological and psychiatric diseases, including Alzheimer’s disease, Parkinson’s disease, brain tumor, stroke, seizures, and schizophrenia (Haller et al., 2016; Le et al., 2014; Oura et al., 2018; Schneider et al., 2019). In particular, the development of three-dimensional (3D) ASL-MRI with GRASE (a technique combining gradient rapid echo and spin echo) or FSE (fast spin echo) acquisition dramatically improves the perfusion image quality with a high signal-to-noise ratio and spatial-resolution (Alsop et al., 2015; Uetani et al., 2018). However, no previous investigation has focused on the ability of ASL to diagnose and evaluate brain perfusion in NPSLE patients.

Therefore, the purpose of this study was to investigate the underlying perfusion pattern of NPSLE and non-NPSLE using noninvasive 3D ASL-MRI and to evaluate its clinical significance.

2 | MATERIALS AND METHODS

2.1 | Subjects

From January 2017 to February 2018, a total of 111 female subjects, including 40 clinically diagnosed NPSLE patients (aged 32.75 ± 12.68 years) and 35 non-NPSLE patients (aged 29.24 ± 9.84 years) from the Department of Rheumatology, Peking Union Medical College Hospital and 36 female age-matched NCs (aged 32.50 ± 10.57), were enrolled in this study. SLE and the manifestations of NPSLE were diagnosed and defined according to the American College of Rheumatology (ACR) classification and Hanly B criteria for SLE (Hanly et al., 2010; Singh et al., 2006). The inclusion criteria were as follows: (a) age between 18 and 65 years old; (b) right-handedness; and (c) no contra-indications for MRI. The exclusion criteria were as follows: (a) history of alcohol or drug abuse; (b) history of central nervous system disease, such as Alzheimer’s disease, Parkinson’s disease or depression; (c) lesions in NCs by MRI examination; (d) secondary NPSLE due to other causes or peripheral NPSLE; and (e) poor MRI image quality. The clinical evaluation of current SLE disease activity index by the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) scores, accumulative disease damage index scores by the Systemic Lupus International Collaborating Clinics (SLICC) classification criteria and other clinical variables (including disease duration, total cumulative duration of steroid use, manifestations of SLE, vascular risk factors, and immunological indicators) were recorded (for details, refer to Table 1 and Table S1). According to the above inclusion criteria, exclusion criteria and completeness of clinical information, 9 NPSLE patients were excluded due to incomplete scanning, history of hemicrania or incomplete disease history; 11 non-NPSLE patients were excluded due to incomplete scanning, history of hemicrania, or unclear NP history; and 4 NCs were excluded due to incomplete scanning or poor image quality. In total, 31 NPSLE, 24 non-NPSLE, and 32 NCs were included in the final analysis.

All subjects were informed of the purpose of the collection of their information, and this study was approved by the Human and Animal Ethics Committee of Peking Union Medical College Hospital.
and downsampled into the ASL space. Fourth, partial volume images. Third, the structural images were co-registered to ASL images obtained, as well as the brain mask for the brain subtraction of ASL CSF. Thus, the segmentation of GM and WM probability maps were AC. Second, structural images were segmented into GM, WM, and commissure (AC–P2, Mato et al., 2016). First, the T1w structural and ASL images were reoriented to the anterior commissure (AC). ASL image preprocessing was carried out using the ASAP (Automatic Software for ASL Processing) toolbox (Mato, García-Polo, O’Daly, Hernández-Tamames, & Zelaya, 2016). For whole brain (WB) level comparisons, the mean CBF within GM, WM, and WB (GM + WM) were calculated. A CBF ratio of GM/WM was obtained by dividing the mean CBF within GM by the mean CBF within WM. For voxel level comparisons, voxel-based analysis (VBA) was performed to find the altered CBF of the local brain regions.

2.2 | Image acquisition

High-resolution 3D T1-weighted and 3D ASL MRI imaging was performed for each subject in a GE 3T MR scanner with a 32-channel receiving coil (GE MR750, GE Healthcare). The 3D T1w images were obtained by a 3D T1 MPRAGE (Magnetic Prepared RApid Gradient Echo) sequence with the following parameters: TR/TE = 1,600 ms/10.5 ms; flip angle = 9; field of view = 240 mm × 240 mm × 160 mm; acquisition voxel = 1 mm × 1 mm × 1 mm; sense factor 1 for slice encoding direction and 2 for phase encoding direction; and acquisition time = 6 min. The 3D pseudocontinuous ASL images were obtained by a 3D TSE sequence with the following parameters: TR/TE = 4,844 ms/10.5 ms; flip angle = 111°; field of view = 240 mm × 240 mm; acquisition voxel = 1.875 mm × 1.875 mm × 4 mm; slice number = 36; number of signal average = 1; labeling duration = 1,500 ms; postlabeling delay time = 2,000 ms; acquisition time = 3 min 34 s. Additionally, axial 3 mm FLAIR images were acquired to assess WM lesions.

2.3 | Image preprocessing

ASL image preprocessing was carried out using the ASAP (Automatic Software for ASL Processing) toolbox (Mato, García-Polo, O’Daly, Hernández-Tamames, & Zelaya, 2016). First, the T1w structural and ASL images were reoriented to the anterior commissure–posterior commissure (AC–PC) plane, and the image origin was set to the AC. Second, structural images were segmented into GM, WM, and CSF. Thus, the segmentation of GM and WM probability maps were obtained, as well as the brain mask for the brain subtraction of ASL images. Third, the structural images were co-registered to ASL images and downsampled into the ASL space. Fourth, partial volume correction (PVC) was performed using Asllani estimates in ASL image space, which could estimate the CBF for GM and WM independently (Mato et al., 2016). Then, the subtracted and PVC ASL images within the brain mask were normalized into the MNI space (voxel values were interpolated and upsampled into 2 mm × 2 mm × 2 mm) based on the co-registration and segmentation nonlinear transformation information. Finally, the corrected CBF images of GM and WM were smoothed with a 3D Gaussian kernel (full-width at half maximum, FWHM = 6 mm × 6 mm × 6 mm).

For whole brain (WB) level comparisons, the mean CBF within GM, WM, and WB (GM + WM) were calculated. A CBF ratio of GM/WM was obtained by dividing the mean CBF within GM by the mean CBF within WM. For voxel level comparisons, voxel-based analysis (VBA) was performed to find the altered CBF of the local brain regions.

2.4 | Statistical analysis

Statistical analyses were carried out using IBM SPSS statistics Version 25 and the DPABI toolbox (a toolbox for Data Processing & Analysis of Brain Imaging. Release V3.1; Yan, Wang, Zuo, & Zang, 2016). For measurement data, parametric ANOVA or nonparametric Kruskal–Wallis H analysis was carried out and followed by corresponding post hoc two-sample tests (Tukey’s test for parametric analysis and the Mann–Whitney U test for nonparametric analysis). For categorical data, Fisher’s exact test was carried out. For ASL images, voxel-based statistical analysis was performed using ANOVA with age as a covariate, followed by a pairwise two-sample t-test with 5,000 permutations to define the t-value threshold. An uncorrected p < .01 and cluster size >30 voxels were considered to be a significant difference. The Pearson correlation coefficient or the Spearman rank correlation.
with age as a covariate, was applied to find the relationship between the values extracted from brain regions, WM lesions and the clinical evaluations (SLEDAI, SLICC, disease duration, and the total cumulative duration of steroid use). For the above analysis, a \( p < .05 \) was considered a significant difference. Receiver operating characteristic (ROC) analysis was carried out to differentiate NPSLE from non-NPSLE by the CBF of the WB level or voxel level, which showed significant differences between NPSLE and non-NPSLE. The cut-off value was determined according to the maximum Youden index.

2.5 | Support vector machine learning

Support vector machine (SVM) with a Gaussian kernel function based on LIBSVM (Library for Support Vector Machines) and MATLAB scripts (MATLAB 2014b) was adopted for the classification of NPSLE and non-NPSLE patients and NCs (Chang & Lin, 2011). The mean CBF values extracted from the brain regions according to voxel level statistical results were used as features for the classification. Leave-one-out cross validation (LOOCV) was applied to SVM training and predictions. The accuracy, sensitivity, specificity, precision, recall, and F1-score were used for the SVM performance evaluation.

3 | RESULTS

3.1 | General demographics and clinical characteristics

The subjects were all females. There was no significant difference in age between NPSLE and non-NPSLE patients and NCs. Significant differences were identified between NPSLE and non-NPSLE patients for SLEDAI and SLICC scores but not for disease duration, total cumulative duration of steroid use or WM lesion volumes (for a WM lesion distribution map, see Figure S1). NPSLE patients presented different clinical neurological symptoms including seizures or epilepsy (14, 45.2%), cognitive disorders (12, 38.7%), mood disorders (9, 29.0%), neuromyelitis optica spectrum disorders (NMOSD) (9, 29.0%), headache (8, 25.8%), large vessel stroke (6, 19.4%), psychosis (6, 19.4%), and acute disturbances of consciousness (5, 16.1%). For more clinical information, refer to Table 1 and Table S1.

3.2 | WM lesions

Twenty-three NPSLE and six non-NPSLE patients showed WM lesions on FLAIR images. There was a significant difference in the incidence of WM lesions between NPSLE and non-NPSLE patients \((p < .001\), refer to Table S1), but there was no significant difference in WM lesion volumes \((p = .469\). As the WM lesion distribution map (Figure S1) shows, the WM lesions were mainly distributed within the periventricular and deep WM.

3.3 | Perfusion abnormalities

The WB level results are listed in Table 1. The ratio of GM/WM showed a decreasing pattern for NC–non-NPSLE–NPSLE. Significant differences were found for NCs versus non-NPSLE patients and for non-NPSLE versus NPSLE patients in the CBF ratio of GM/WM.

VBA was performed for WM and GM separately. Figure 1 shows the results of WM and GM for non-NPSLE versus NPSLE patients, NCs versus non-NPSLE patients, and NCs versus NPSLE patients, respectively. The details are presented in Table 2.

Compared to NCs, NPSLE patients demonstrated decreased GM CBF in the bilateral superior and middle temporal gyrus, parts of the frontal gyrus and bilateral middle cingulum gyrus. Increased CBF was seen in WM located in the pons, right temporal lobe, bilateral frontal lobe, bilateral partial lobe, and bilateral limbic lobe, and decreased CBF was seen in the corpus callosum in NPSLE patients.

Non-NPSLE patients showed increased GM CBF predominantly in the bilateral cerebellum, right temporal gyrus, and left lingual gyrus and showed decreased CBF in the right inferior frontal gyrus compared to NCs. Distributed WM showed increased CBF, which included the WM located in the brainstem, bilateral cerebellum lobes, inferior temporal lobe, right middle temporal lobe, bilateral middle occipital lobe, left lingual/calcarine/cuneus, left inferior partial lobe, right cingulate/precentral lobe, and parts of the frontal lobe.

![FIGURE 1](image-url)  VBA results (t-value distribution) of GM and WM for NCs versus non-NPSLE, NCs versus NPSLE, and non-NPSLE versus NPSLE (two-sample t-test with 5,000 permutations to define the t-value threshold. An uncorrected \( p < .01 \) and cluster size>30 voxels were considered to indicate a significant difference. The color bar shows the range of the t-values displayed in the figures.)
| Between groups | GM or WM | Cluster index | Brain regions | No. of voxels | Peak t value | MNI coordinates (mm) | Correlation with SLEDAI | Correlation with SLICC |
|----------------|---------|---------------|---------------|--------------|--------------|----------------------|-------------------------|------------------------|
| Non-NPSLE–NPSLE | GM      | 1             | Right cerebellum posterior lobe | 41           | 3.05         | 26 −84 −24           | −0.33 (0.015)           |                        |
|                 |         | 2             | Left inferior/middle frontal gyrus | 31           | 3.50         | −46 44 14            |                          |                        |
|                 |         | 3             | Right superior frontal gyrus | 49           | 3.72         | 30 50 32             | −0.28 (0.044)           |                        |
|                 |         | 4             | Right middle frontal gyrus | 37           | 3.63         | 36 6 58              | −0.38 (0.005)           |                        |
|                 |         | 5             | Left superior frontal gyrus | 45           | 3.59         | −20 20 60            | −0.29 (0.034)           |                        |
|                 | WM      | 1             | Corpus callosum | 34           | 3.28         | 0 −16 26             | −0.32 (0.017)           |                        |
| NC–Non-NPSLE    | GM      | 1             | Part of right cerebellum posterior lobe | 137          | −3.03        | 8 −62 −28            |                          |                        |
|                 |         | 2             | Part of left cerebellum posterior lobe | 144          | −2.99        | −42 −60 −42          |                          |                        |
|                 |         | 3             | Part of right cerebellum posterior lobe | 235          | −2.85        | 40 −68 −36           |                          |                        |
|                 |         | 4             | Part of right cerebellum anterior/posterior lobe | 99           | −3.37        | 32 −48 −36           |                          |                        |
|                 |         | 5             | Part of left cerebellum anterior lobe | 41           | −2.91        | −30 −52 −34          |                          |                        |
|                 |         | 6             | Part of left cerebellum posterior lobe | 136          | −3.00        | −6 −64 −36           |                          |                        |
|                 |         | 7             | Right inferior/middle temporal gyrus | 39           | −2.69        | 56 −42 −12           | −0.27 (0.045)           |                        |
|                 |         | 8             | Part of right cerebellum posterior lobe | 40           | −2.66        | 20 −60 −20           |                          |                        |
|                 |         | 9             | Left lingual gyrus | 42           | −3.08        | −22 −82 −14          | −0.35 (0.010)           |                        |
|                 |         | 10            | Right inferior frontal gyrus | 77           | 3.73         | 56 30 −2             |                          |                        |
|                 |         | 11            | Right middle temporal gyrus | 85           | −3.37        | 50 −54 4             | −0.29 (0.035)           |                        |
|                 | WM      | 1             | Brainstem (right and left) | 38           | −2.74        | 2 −42 −52            |                          |                        |
|                 |         | 2             | Left cerebellum anterior/posterior lobe | 144          | −3.41        | −26 −60 −42          |                          |                        |
|                 |         | 3             | Left and right brainstem (pons) | 318          | −3.19        | −6 −28 −44           |                          |                        |
|                 |         | 4             | Right cerebellum anterior/posterior lobe | 305          | −3.19        | 22 −60 −34           |                          |                        |
|                 |         | 5             | Left inferior temporal lobe | 30           | −2.43        | −50 −32 −20          |                          |                        |
|                 |         | 6             | Right inferior/middle temporal lobe; right middle occipital lobe | 420          | −3.06        | 52 −26 −20           |                          |                        |
|                 |         | 7             | Left lingual lobe | 53           | −3.56        | −14 −88 −10          |                          |                        |
|                 |         | 8             | Right lingual/calcarine/cuneus | 169          | −4.00        | 18 −92 −6            |                          |                        |
|                 |         | 9             | Left (middle) occipital lobe | 73           | −3.23        | −26 −78 −4           |                          |                        |
|                 |         | 10            | Left sub-gyr( fronto) lobe | 119          | −2.65        | −26 42 0             |                          |                        |
|                 |         | 11            | Right sub-gyr (frontal lobe) | 143          | −2.41        | 24 34 18             |                          |                        |
|                 |         | 12            | Left precentral; inferior parietal gyrus | 554          | −3.13        | −42 −28 30           |                          |                        |

(Continues)
Compared to non-NPSLE patients, decreased GM CBF was found in the right cerebellum posterior lobe, left inferior frontal gyrus, bilateral superior frontal gyrus, and bilateral middle frontal gyrus, while decreased WM CBF was found in the corpus callosum in NPSLE patients.

### 3.4 Relationship between perfusion measures, clinical variables, and WM lesion volume

Abnormal CBF within several brain regions (e.g., cingulate, corpus callosum, and bilateral frontal gyrus) showed weak correlations with clinical information including SLEDAI and SLICC scores and showed no significant correlation with disease duration, total cumulative duration of steroid use, or WM lesion volume when age was used as a covariate. The details of this analysis are shown in Table 2.

We found no significant association between CBF measures and other clinical information (e.g., renal disorder) or laboratory parameters (e.g., anti-dsDNA) related to the manifestation of SLE, vascular risk factors and immunological indicators.

### 3.5 ROC analysis to differentiate NPSLE from non-NPSLE

Differentiating non-NPSLE and NPSLE is a challenge in clinical practice. In this work, the ratio of GM/WM was used to distinguish non-
TABLE 3  Details of ROC analysis for differentiating NPSLE from non-NPSLE by the CBF ratio of GM/WM and CBF within the local brain regions detected by VBA

| Region                        | AUC     | Cut-off value | Youden index | Sensitivity (%) | Specificity (%) |
|-------------------------------|---------|---------------|--------------|-----------------|-----------------|
| Ratio of GM/WM                | 0.737   | 1.96          | 0.478        | 83.3            | 64.5            |
| Right cerebellum posterior lobe | 0.742   | 44.04         | 0.381        | 83.3            | 54.8            |
| Left inferior/middle frontal Gyrus | 0.743   | 38.54         | 0.446        | 83.3            | 61.3            |
| Right superior frontal Gyrus  | 0.738   | 32.34         | 0.492        | 75.0            | 74.2            |
| Right middle frontal Gyrus    | 0.780   | 26.03         | 0.492        | 75.0            | 74.2            |
| Left superior frontal Gyrus   | 0.770   | 27.45         | 0.441        | 66.7            | 77.4            |
| Corpus callosum               | 0.738   | 17.08         | 0.433        | 91.7            | 51.6            |

NPSLE from NPSLE. The ROC analysis results are shown in Table 3 and Figure S2. The GM/WM ratio has a moderate ability to distinguish NPSLE from non-NPSLE, with an AUC of 0.737 and a cut-off value of 1.96 (sensitivity = 83.3%, specificity = 64.5%, and Youden index = 0.478).

We also investigated the ability of regional brain measurements to differentiate NPSLE from non-NPSLE. ROC analysis showed that all the statistically significant brain regions, such as the right cerebellum posterior lobe, bilateral superior and middle frontal gyrus and corpus callosum, showed a moderate performance (AUC > 0.7) for differentiating non-NPSLE from NPSLE. The details of this analysis are shown in Table 3 and Figure 2.

3.6 Classification by SVM

The classification results are listed in Table 4. CBF in the corpus callosum can distinguish non-NPSLE from NPSLE with high accuracy (83.6%), sensitivity (80.6%), and specificity (87.5%) and is superior to the method using brain regions within GM. For NCs versus non-NPSLE and NCs versus NPSLE, the combined features derived from GM and WM showed good classification. For NCs versus non-NPSLE + NPSLE, the classification results were good (accuracy of 87.4%, sensitivity of 89.1%, and specificity of 84.4%); however, differentiating NCs + non-NPSLE from NPSLE showed low sensitivity (61.3%).

4 DISCUSSION

In the present study, we identified different cerebral perfusion patterns between non-NPSLE and NPSLE patients. In non-NPSLE patients, within GM, CBF was decreased in the right inferior frontal gyrus but increased in the bilateral cerebellum, right temporal gyrus and left lingual gyrus compared to NCs. Within WM, distributed increased CBF was observed compared to NCs. In NPSLE patients, CBF in the bilateral frontal gyrus, temporal gyrus and middle cingulum gyrus decreased compared to that in NCs, while CBF was increased in most of the WM regions except the corpus callosum. The main differences between NPSLE and non-NPSLE were in the frontal lobe and cerebellum (GM) and in the corpus callosum (WM). Perfusion patterns can accurately classify NPSLE and non-NPSLE patients with CBF, which could be a potential imaging biomarker for the differentiation of non-NPSLE and NPSLE.

Our data demonstrated an increase in GM perfusion in non-NPSLE patients and a decrease in NPSLE patients, implying the dynamic progression of perfusion alterations. Cohen et al. (2017) proposed that vascular injury may occur in all patients with SLE, but primary NP manifestations occurred only after exceeding a certain threshold of ischemic injury, which is consistent with our findings. CBF significantly increased in GM in the temporal gyrus, cingulate gyrus, and cerebellum regions and in widespread WM in non-NPSLE patients compared with NCs. We hypothesized that this result may be caused by a compensatory mechanism in response to ischemia or injury, which was consistent with previous fMRI studies showing hyperactivities and hyperconnectivity within certain specific networks (e.g., the sensorimotor network) (Mikdashi, 2016; Niu et al., 2018; Nystedt et al., 2018; Papadaki et al., 2014; Wu et al., 2018; Zhang et al., 2017). However, in NPSLE patients, along with widespread vasculopathy and thrombosis, the perfusion of these brain regions was significantly decreased, which means a large reduction in compensatory capacity when the damage exceeded the threshold. In this work, 18 NPSLE patients showed obvious cerebral atrophy (only four non-NPSLE patients showed cerebral atrophy), which could also account for GM hypoperfusion. Non-NPSLE and NPSLE might share a similar vessel compensatory mechanism within WM, which presented in higher perfusion in distributed areas within WM both in non-NPSLE and NPSLE patients. This finding is consistent with a previous DSC study showing elevated CBF and CBV within normal-appearing WM in SLE patients compared to that in NCs (Gasparovic et al., 2010). The hyperperfusion within WM might also be attributed to potential vascular dysfunction caused by evaluated blood pressure in SLE patients (Gasparovic, Qualls, Greene, Sibbitt, & Roldan, 2012).

Histopathological studies revealed that nonspecific focal vasculopathy appeared in non-NPSLE, while diffuse vasculopathy and microthrombi were commonly found in NPSLE, which is the possible pathological basis for different patterns of perfusion abnormalities (Cohen et al., 2017; Sarbu, Sarbu, Bargallo, & Cervera, 2018; Sibbitt et al., 2010). Because of its vasculopathy nature, NPSLE is considered a subtype of inflammatory and immunologically mediated small vessel diseases. The corpus callosum is a key WM structure connecting hemisphere projection fibers. This territory is prone to be affected by...
hemodynamic impairment. Previous work found a decreased NAA/Cr ratio or an increased Cho/Cr ratio within the posterior cingulate cortex and posterior region of the corpus callosum, especially in hypoperfused areas (Castellino et al., 2005; Wang et al., 2012). Additionally, the corpus callosum was the region most commonly reported to have abnormal diffusion parameters (including fractional anisotropy [FA] and mean diffusivity [MD]). Together with our finding of abnormal perfusion in the corpus callosum, these findings indicated that the corpus callosum was one of the fibers specifically damaged in SLE patients. This damage was more pronounced in NPSLE patients, indicating that the corpus callosum measurement could be a sensitive biomarker for defining NPSLE (Costallat et al., 2018; Lee et al., 2015; Wang et al., 2012). This perfusion pattern in the corpus callosum needs to be validated in a large sample with a longitudinal design and Figure 2 ROC analysis of CBF extracted from statistically significant brain regions to differentiate NPSLE and non-NPSLE. The red point indicates the cut-off value.
has the potential to be an imaging biomarker for defining SLE patients vulnerable to progress to NPSLE.

Some previous works showed conflicting results demonstrating the hypoperfusion of GM and WM in both NPSLE and non-NPSLE patients (Papadaki et al., 2018; Wang et al., 2012). This discordant information may be due to variations in the sample sizes, MR scanners or analysis methods of these studies (Emmer et al., 2010; Wang et al., 2012; Zimny et al., 2014). For example, previous works performed CBF normalization with the assumption of stable perfusion within some brain regions (such as the cerebellum). However, we found that the perfusion within the cerebellum showed a significant difference between NPSLE and non-NPSLE patients, indicating that CBF in the cerebellum was altered by SLE disease. Therefore, we did not normalize cerebral CBF with CBF in the cerebellum. The alterations in cerebellum CBF and their relationship with cerebral perfusion should be studied in future studies.

In the current study, CBF in the right cerebellum, posterior lobe, right middle frontal gyrus, and corpus callosum were correlated with SLICC measures in NPSLE patients, suggesting that the hypoperfusion of certain cerebral regions could be an imaging biomarker for predicting prognosis. A correlation was observed between CBF in the left lingual gyrus (GM), right cingulate/precentral lobe (WM), and SLEDAI measures in non-NPSLE patients, implying that the hypoperfusion of these brain areas could reflect high disease activity that requires aggressive treatment.

The differentiation of NPSLE patients from non-NPSLE patients and NCs is essential in clinical practice. The previously proposed imaging measures have high sensitivity (80–100%) but relatively low specificity (<67%) with PET, SPECT or DSC-MRI (Cervera et al., 2006; Emmer et al., 2010; Kao, Ho, et al., 1999; Kao, Lan, et al., 1999). In the present study, we found that the differentiation of NPSLE patients from non-NPSLE patients could reach a high sensitivity and specificity of 71.0 and 75.0%, respectively, for GM features; 83.6 and 80.6%, respectively, for WM features; and 83.6 and 80.6%, respectively, for combined GM and WM features. Using a simple cut-off value of 1.96 for the GM/WM CBF ratio, we can differentiate NPSLE and non-NPSLE patients with a sensitivity of 83.3% and a specificity of 64.5%. In particular, CBF in the corpus callosum showed good differential performance using SVM, implying that this measure could be a noninvasive and objective imaging biomarker for the early accurate diagnosis of NPSLE, especially for subclinical and atypical NPSLE.

There are some limitations to this study. First, this study is a cross-sectional single MRI modality (perfusion) study with a relatively small sample size from a single center. A longitudinal study using multimodality techniques, such as structural and functional MRI and PET/SPECT, in a large sample size from multi-site centers is warranted to validate the current findings. Second, cognitive and neuropsychiatric assessments were not comprehensively performed, hindering the investigation between perfusion and neuropsychiatric scores. Third, the lesion effect on CBF alterations in SLE is not fully demonstrated in the current study. Further study with longitudinal data and comprehensive analysis is required to investigate the association between lesions and CBF in SLE patients (Gasparovic et al., 2010). Fourth, SVM analysis was performed according to the current state-of-the-art approach using a cross-validation approach, which needs further validation in larger multi-site studies in a clinical scenario (Haller, Lovblad, Giannakopoulos, & Van De Ville, 2014).

## 5 CONCLUSION

Different brain perfusion patterns were observed in NPSLE and non-NPSLE patients using the noninvasive ASL technique and were

### TABLE 4 SVM classification results for different groups

| Classification groups | Features (No.) | Accuracy (%) | Sensitivity (%) | Specificity (%) | Precision (%) | Recall (%) | F1-score |
|-----------------------|----------------|--------------|-----------------|----------------|---------------|------------|----------|
| non-NPSLE versus NPSLE | GM (5) | 72.7 | 71.0 | 75.0 | 78.6 | 71.0 | 0.746 |
|                        | WM (1) | 83.6 | 80.6 | 87.5 | 89.3 | 80.6 | 0.847 |
|                        | GM + WM (6) | 83.6 | 80.6 | 87.5 | 89.3 | 80.6 | 0.847 |
| NC versus non-NPSLE    | GM (11) | 80.4 | 70.8 | 87.5 | 81.0 | 70.8 | 0.756 |
|                        | WM (15) | 76.8 | 50.0 | 96.7 | 92.3 | 50.0 | 0.649 |
|                        | GM + WM (26) | 83.9 | 70.8 | 93.8 | 89.5 | 70.8 | 0.791 |
| NC versus NPSLE        | GM (10) | 76.2 | 80.6 | 71.9 | 73.5 | 80.6 | 0.769 |
|                        | WM (5) | 82.5 | 71.0 | 93.8 | 91.7 | 71.0 | 0.800 |
|                        | GM + WM (15) | 84.1 | 77.4 | 90.6 | 88.9 | 77.4 | 0.828 |
| NC versus non-NPSLE + NPSLE | GM (26) | 86.2 | 92.7 | 75.0 | 86.4 | 92.7 | 0.895 |
|                        | WM (21) | 81.6 | 94.5 | 59.4 | 80.0 | 94.5 | 0.867 |
|                        | GM + WM (47) | 87.4 | 89.1 | 84.4 | 90.7 | 89.1 | 0.899 |
| NC + non-NPSLE versus NPSLE | GM (26) | 79.3 | 58.1 | 91.1 | 78.3 | 58.1 | 0.667 |
|                        | WM (21) | 81.6 | 61.3 | 92.9 | 82.6 | 61.3 | 0.704 |
|                        | GM + WM (47) | 82.8 | 61.3 | 94.6 | 86.4 | 61.3 | 0.717 |

ZHUO ET AL. 763
correlated with clinical scores, implying that perfusion characteristics could be a useful biomarker reflecting pathophysiological alterations and identifying NPSLE.

ACKNOWLEDGMENTS

Li Su’s contribution to this work has been supported by Xiaofeng Zeng and the fellows of the department of Rheumatology of Peking Union Medical College Hospital. This work was supported by the National Science Foundation of China (Nos. 81571597, 81571631, and 81870958), the Beijing Natural Science fund (No.7133244), the Beijing Nova Program (xx2013045), and The Chinese National Key Research R&D Program (Nos. 2017YFC0907601, 2017YFC0907602, and 2017YFC0907603).

CONFLICT OF INTEREST

None declared.

AUTHOR CONTRIBUTIONS

The project was designed, conceived and planned by Y.L., X.Z., and H.L. The data acquisition was performed by L.S. The data were processed and analyzed by Z.Z. The article was written and edited by Z.Z. and L.S. The article was revised by Y.D., J.H., X.Q., and S.H. All authors approved the final version of the manuscript.

PATIENT CONSENT FOR PUBLICATION

Obtained.

DATA AVAILABILITY STATEMENT

The data that support the findings in this study are available from the corresponding author upon request.

ORCID

Sven Haller https://orcid.org/0000-0001-7433-0203
Haiyun Li https://orcid.org/0000-0001-7635-3468
Yaou Liu https://orcid.org/0000-0002-6635-8705

REFERENCES

Alsop, D. C., Detre, J. A., Golay, X., Günther, M., Hendrikse, J., Hernandez-Garcia, L., … Zaharchuk, G. (2015). Recommended implementation of arterial spin-labeled perfusion MRI for clinical applications: A consensus of the ISMRM perfusion study group and the European consortium for ASL in dementia. Magnetic Resonance in Medicine, 73(1), 102–116. https://doi.org/10.1002/mrm.25197
Castellino, G., Govoni, M., Padovan, M., Colamussi, P., Borrelli, M., & Trotta, F. (2005). Proton magnetic resonance spectroscopy may predict future brain lesions in SLE patients: A functional multi-imaging approach and follow up. Annals of the Rheumatic Diseases, 64(7), 1022–1027. https://doi.org/10.1136/ard.2004.026772
Castellino, G., Govoni, M., Giacuzzo, S., & Trotta, F. (2008). Optimizing clinical monitoring of central nervous system involvement in SLE. Autoimmunity Reviews, 7(4), 297–304. https://doi.org/10.1016/j.aurt.2007.11.022
Castellino, G., Padovan, M., Bortoluzzi, A., Borrelli, M., Feggi, L., Caniatti, M. L., … Govoni, M. (2008). Single photon emission computed tomography and magnetic resonance imaging evaluation in SLE patients with and without neuropsychiatric involvement. Rheumatology, 47(3), 319–322. https://doi.org/10.1093/rheumatology/kem354
Cervera, R., Abarca-Costalaga, M., Abramovicz, D., Allegri, F., Annunziata, P., Aydintug, A. O., … Vivancos, J. (2006). Systemic lupus erythematosus in Europe at the change of the millennium: Lessons from the “euro-lupus project”. Autoimmunity Reviews, 5(3), 180–186. https://doi.org/10.1016/j.autrev.2005.06.004
Chang, C. C., & Lin, C. J. (2011). LIBSVM: A library for support vector machines. ACM Transactions on Intelligent Systems and Technology, 2(3), 27. https://doi.org/10.1145/1961189.1961199
Cohen, D., Rijnink, E. C., Nabuurs, R. J., Steup-Beekman, G. M., Versluis, M. J., Emmer, B. J., … Bajema, I. M. (2017). Brain histopathology in patients with systemic lupus erythematosus: Identification of lesions associated with clinical neuropsychiatric lupus syndromes and the role of complement. Rheumatology, 54(1), 77–86. https://doi.org/10.1093/rheumatology/kew341
Costallat, B. L., Ferreira, D. M., Lapa, A. T., Rittner, L., Costallat, L. T. L., & Appenzeller, S. (2018). Brain diffusion tensor MRI in systemic lupus erythematosus: A systematic review. Autoimmunity, Reviews, 17(1), 36–43. https://doi.org/10.1016/j.autrev.2017.11.008
Emmer, B. J., van Osch, M. J., Wu, O., Steup-Beekman, G. M., Steens, S. C., Huizinga, T. W., … van der Grond, J. (2010). Perfusion MRI in Neuropsychiatric systemic lupus Erythematosus. Journal of Magnetic Resonance Imaging, 32(2), 283–288. https://doi.org/10.1002/jmri.22251
Ercan, E., Ingo, C., Tritanian, O., Magro-Checa, C., Smith, A., Smith, S., … Ronesi, I. (2015). A multimodal MRI approach to identify and characterize microstructural brain changes in neuropsychiatric systemic lupus erythematosus. NeuroImage, Clinical, 8, 337–344. https://doi.org/10.1016/j.nicl.2015.05.002
Gasparovic, C., Qualls, C., Greene, E. R., Sibbitt, W. L. J., & Roldan, C. A. (2012). Blood pressure and vascular dysfunction underlie elevated cerebral blood flow in systemic lupus erythematosus. The Journal of Rheumatology, 39, 752–758. https://doi.org/10.3899/jrheum.110538
Gasparovic, C. M., Roldan, C. A., Sibbitt, W. L. J., Qualls, C. R., Mullins, P. G., Sharrar, J. M., … Bockholt, H. J. (2010). Cerebral blood flow and volume in systemic lupus measured by dynamic susceptibility contrast magnetic resonance imaging. The Journal of Rheumatology, 37(9), 1834–1843. https://doi.org/10.3899/jrheum.091276
Hallier, S., Lovblad, K. O., Giannakopoulos, P., & Van De Ville, D. (2014). Multivariate pattern recognition for diagnosis and prognosis in clinical neuroimaging: State of the art, current challenges and future trends. Brain Topography, 27(3), 329–337. https://doi.org/10.1007/s10548-014-0360-z
Hallier, S., Zaharchuk, G., Thomas, D. L., Lovblad, K. O., Barkhof, F., & Golay, X. (2016). Arterial spin labeling perfusion of the brain: Emerging clinical applications. Radiology, 281(2), 337–356. https://doi.org/10.1148/radiol.2016150789
Hanly, J. G., Urowitz, M. B., Su, L., Bae, S. C., Gordon, C., Wallace, D. J., … Farewell, V. (2010). Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases, 69(3), 529–535. https://doi.org/10.1136/ard.2008.106351
Kao, C. H., Ho, Y. J., Lan, J. L., Changlai, S. P., Liao, K. K., & Chieng, P. U. (1999). Discrepancy between regional cerebral blood flow and glucose metabolism of the brain in systemic lupus erythematosus patients with normal brain magnetic resonance imaging findings. Arthritis and
diffusion-tensor imaging. Lupus, 23(1), 10–19. https://doi.org/10.1177/0961203313511556

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of this article.

How to cite this article: Zhuo Z, Su L, Duan Y, et al. Different patterns of cerebral perfusion in SLE patients with and without neuropsychiatric manifestations. *Hum Brain Mapp.* 2020;41:755–766. https://doi.org/10.1002/hbm.24837